Key Takeaways From Heart Failure Clinical Trials

EP: 1.Identifying Key Risk Factors for Heart Failure

EP: 2.Socioeconomic Factors Impacting Development of Cardiac Disease

EP: 3.Distinguishing Between Heart Failure Classifications

EP: 4.Staging Heart Failure and the Importance of Early Diagnosis

EP: 5.The Role of the Primary Care Physician in Heart Failure Management

EP: 6.Four Pillars of Heart Failure Therapy

EP: 7.Selecting Optimal First-line Therapy for Patients Diagnosed with Heart Failure

Now Viewing

EP: 8.Key Takeaways From Heart Failure Clinical Trials

EP: 9.Navigating the Patient Journey Through Heart Failure Diagnosis

EP: 10.Strategies for Treating Preserved Ejection Fraction (HFpEF)

EP: 11.Treatment Optimization Challenges Associated With Heart Failure

EP: 12.Financial Barriers Impeding Optimal Heart Failure Treatment

EP: 13.Trajectory of Heart Failure Treatment Strategies

EP: 14.Key Takeaways from Experts in Heart Failure Management

This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses knowing when to deviate from guideline-directed heart failure therapy, emphasizing the expert clinician’s role in individualizing care. Albert notes renal concerns previously limited use of renin-angiotensin-aldosterone system (RAAS) inhibitors and mineralocorticoid receptor antagonists (MRAs), but current evidence shows overall kidney benefits with angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors despite initial changes in function. Understanding drugs’ mechanisms and adverse effect profiles prevents inappropriate discontinuation. Axsom emphasizes how multidisciplinary teams help monitor patients starting new therapies, allowing providers to “ride out” transient changes. Desai stresses that all clinicians should initiate guideline-directed treatments using standard protocols. Axsom reviews data showing the ARNIs (sacubitril-valsartan) reduce mortality by 16% versus angiotensin-converting enzyme (ACE) inhibitors in heart failure with reduced ejection fraction (HFrEF), leading to its favored status. However, it should not be started in unstable, symptomatic patients. Desai adds that this mortality benefit was against active comparators, not placebo, underscoring the need to convert stable ACE inhibitor patients to ARNI therapy. Overall, expertise means maximizing evidence-based therapies through urgent optimization, not just following old habits. But multidisciplinary teams support appropriate individualization when challenges arise.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.